MedTrace Logo

Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections

NCT02492594 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 244

Last updated 2021-01-12

No results posted yet for this study

Summary

Invasive fungal infections (IFI) in immunocompromised patients pose a major challenge for diagnostics designed to permit timely onset of appropriate treatment. The aim of the current clinical-diagnostic studies, one in in pediatric and one in adult patients at high risk of IFI, is to test newly developed diagnostic approaches to invasive fungal infections in relation to established procedures. The studies will be performed in a prospective, blinded fashion, and represent a work package within the FUNGITECT grant supported by the European Commission. The studies will focus on analyses of blood-samples from patients with febrile neutropenia during treatment of acute leukaemia and other tumour entities, and patients undergoing allogeneic stem cell transplantation treated with intensive chemotherapy.

Conditions

  • Systemic Mycosis

Interventions

OTHER

Peripheral blood sampling

Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia: * at the start of neutropenic fever * after 24 hours * after 48 hours * before the start of antimycotic therapy, if pertinent * at the end of antimycotic therapy, if pertinent

Sponsors & Collaborators

  • St. Anna Kinderkrebsforschung

    lead OTHER

Principal Investigators

  • Thomas Lion, Prof MD PhD MSc · St. Anna Kinderkrebsforschung

Eligibility

Min Age
6 Months
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • Austria
  • Netherlands
  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02492594 on ClinicalTrials.gov